



COVID-19 Update

Dr Mark Cunningham-Hill
Medical Director NEBGH


Monday July 26th, 2021



The Delta Variant


Daily new confirmed COVID-19 cases per million people

Shown is the rolling 7-day average. The number of confirmed cases is lower than the number of actual cases; the main reason for that is limited testing.




Daily new confirmed COVID-19 cases per million people

Shown is the rolling 7-day average. The number of confirmed cases is lower than the number of actual cases; the main reason for that is limited testing.




West Midwest South Northeast



[About this data](#)


Hot spots

AVERAGE DAILY CASES PER 100,000 PEOPLE IN PAST WEEK



DELTA VARIANT PREVALENCE IN THE U.S.

COVID-19 DELTA VARIANT CASES BY REGION, AS A SHARE OF NEW CASES




SOURCE: CDC

TWO WEEKS PERIOD ENDING JULY 17, 2021

FORTUNE

Vaccine Efficacy and the Delta variant



Vaccines Highly Effective, but Concerns about Delta Variant

Vaccine	Efficacy at preventing disease: D614G & Alpha (B.1.1.7)	Efficacy at preventing infection: D614G & Alpha (B.1.1.7)	Efficacy at preventing disease: Beta (B.1.351), Gamma (P.1), Kappa (B.1.617)	Efficacy at preventing infection: Beta (B.1.351), Gamma (P.1), Kappa (B.1.617)	Efficacy at preventing infection: B.1.617.2 (Delta)	Efficacy at preventing Hospitalization: B.1.617.2 (Delta)
Pfizer/BioNTech	91%	86%	86%	82% (concern with Gamma)	36-88% 32% if partially vaccinated	90-96% if fully vaccinated
Moderna	94%	89%	89%	85%	88% fully vaccinated	Assumed like Pfizer
AstraZeneca-Oxford	74%	52%	35%	31%	67% 33% % 1 dose	92%
Johnson & Johnson (Janssen)	72%	72%	64%	57%	64%	82% - more data needed
Sputnik-V (Gamaleya)	92%	81%	59%	52%	Reported as 90% effective but no data available	ND
Novavax	89%	79%	49%	43%	93%	ND
CoronaVac	50%	44%	32%	28%	ND	ND
Sinopharm	73%	65%	47%	41%	ND	ND
Tianjin CanSino	66%	58%	42%	37%	ND	ND
Covaxin	79%	69%	57%	50%	ND	ND

D614G – Early SARS-CoV-2 – nickname “Doug”

B.1.1.7 – Alpha first identified in the UK

B.1.351 – Beta first identified in South Africa

P.1 – Gamma first identified in Brazil

B.1.617 – earlier version of Kappa and Delta

Breakthrough infections

- CDC counts only breakthrough infections from fully vaccinated people who are hospitalized or die.
 - As of July 19, 2021, >161 million people in the US fully vaccinated against COVID-19


Total number of vaccine breakthrough infections reported to CDC		
Hospitalized or fatal vaccine breakthrough cases reported to CDC	5,914	
Female	2,881	(49%)
People aged ≥65 years	4,392	(74%)
Asymptomatic infections	1,164	(20%)
Hospitalizations*	5,601	(95%)
Deaths†	1,141	(19%)

* 1,529 (27%) of 5,601 hospitalizations reported as asymptomatic or not related to COVID-19.

† 292 (26%) of 1,141 fatal cases reported as asymptomatic or not related to COVID-19.

Vaccine effectiveness[^] by outcome and month vaccinated with second dose, 20/6 - 17/7/2021

Jan-21 Feb-21 Mar-21 Apr-21 All fully vaccinated



[^]Adjusted for age group, sex and epi-week


* 95% confidence interval crosses 0

Is it Delta or Waning Immunity?

- Waning immunity – something we always suspected would happen
 - Studies show antibodies dropping off especially for older individuals
- Delta variant – More infectious and evidence that it does impact vaccine effectiveness to a small or larger degree depending on the vaccine



DATA FROM US AND UK SHOWS
MOST INFECTIONS IN YOUNGER
PROBABLY UNVACCINATED AGE
GROUPS



Breakthrough infections

- We know the vaccines are not 100% effective at stopping all infections
 - **They are great at stopping severe illness, hospitalization and death**
 - Asymptomatic, mild and moderate illnesses were expected - So, no surprise with increasing numbers of cases!
 - As the percentage of fully vaccinated increase, we will see the proportion of COVID cases in fully vaccinated increase
 - The reported high % of any breakthrough infections from Israel may reflect very high testing rates and picking up asymptomatic cases
- We also know the Delta variant is:
 - More infectious
 - That vaccinated people can infect others (but their viral load likely less than the unvaccinated)

Asymptomatic, Mild, Moderate or Severe


No formal definitions

- **Asymptomatic** – no symptoms!
- **Mild** might include a fever, some respiratory symptoms, headaches, dry cough, some aches and pains – may need time off for a day or two
- **Moderate** –mild symptoms but more severe, don't want to or can't get out of bed, increasing breathing issues
- **Severe** – increasing shortness of breath, decreasing oxygen levels, confusion etc..

How the UK's vaccine rollout has dramatically reduced Covid-19 deaths


Cases versus deaths over days 1–50 of the UK's second and third Covid waves

Second Wave



[Get the data](#) • Created with [Datawrapper](#)

Third wave



[Get the data](#) • Created with [Datawrapper](#)

Calculations based on a seven-day rolling average of daily recorded cases and deaths. Second wave is recorded from 8/9/20, third wave is recorded from 14/5/21.
Source: UK Government, ONS


What are the risks?

- Unvaccinated:

- If unvaccinated then high probability of catching COVID as Delta highly infectious
- Real risk of hospitalization and death especially if older or have risk factors – 99% of deaths are unvaccinated people
- Should take precautions –
 - physical distancing, wearing a mask in public, avoid crowded indoor spaces
 - Get vaccinated as soon as possible

- Vaccinated:

- Delta increases the risk of still getting COVID even if vaccinated but likely to be asymptomatic, mild or moderate illness
- Risk of severe illness, hospitalization, needing and ICU or death is low
- No masks and physical distancing? It depends:
 - On number of unvaccinated people
 - Community rates
 - Indoor versus outdoor
 - High-risk individuals in your family or who you encounter regularly



"This one's dedicated to all the people that didn't believe in me when I was getting started."



**KEEP
CALM
AND
PLAY THE
LONG GAME**

The background of the slide features several 3D-rendered coronavirus particles in a deep red color. These particles are spherical with a textured surface and are covered in numerous spike proteins that protrude outwards. They are scattered across the frame, with some appearing in sharp focus and others blurred in the background, creating a sense of depth. The overall lighting is dark, with the red of the viruses providing the primary visual element.

Questions

Upcoming NEBGH virtual events: